Raymond James Financial Inc. Purchases Shares of 18,878 Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Raymond James Financial Inc. bought a new stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 18,878 shares of the company’s stock, valued at approximately $1,256,000. Raymond James Financial Inc. owned 0.47% of Invesco Biotechnology & Genome ETF as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Jane Street Group LLC bought a new stake in shares of Invesco Biotechnology & Genome ETF during the third quarter worth about $295,000. HighTower Advisors LLC grew its holdings in shares of Invesco Biotechnology & Genome ETF by 64.1% in the third quarter. HighTower Advisors LLC now owns 7,101 shares of the company’s stock valued at $494,000 after acquiring an additional 2,774 shares in the last quarter. IHT Wealth Management LLC increased its position in shares of Invesco Biotechnology & Genome ETF by 14.7% during the third quarter. IHT Wealth Management LLC now owns 12,124 shares of the company’s stock valued at $847,000 after acquiring an additional 1,550 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in Invesco Biotechnology & Genome ETF by 52.9% during the fourth quarter. Jones Financial Companies Lllp now owns 2,315 shares of the company’s stock worth $154,000 after acquiring an additional 801 shares during the period. Finally, Massachusetts Wealth Management boosted its position in Invesco Biotechnology & Genome ETF by 1.3% in the fourth quarter. Massachusetts Wealth Management now owns 18,414 shares of the company’s stock worth $1,225,000 after purchasing an additional 230 shares during the last quarter.

Invesco Biotechnology & Genome ETF Price Performance

Shares of NYSEARCA:PBE opened at $63.30 on Thursday. The business has a fifty day moving average price of $66.90 and a two-hundred day moving average price of $68.24. Invesco Biotechnology & Genome ETF has a 1 year low of $59.32 and a 1 year high of $72.84. The company has a market capitalization of $229.78 million, a PE ratio of 23.00 and a beta of 0.80.

Invesco Biotechnology & Genome ETF Increases Dividend

The company also recently disclosed a dividend, which was paid on Friday, March 28th. Investors of record on Monday, March 24th were paid a $0.0341 dividend. This is a boost from Invesco Biotechnology & Genome ETF’s previous dividend of $0.01. The ex-dividend date was Monday, March 24th.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.